© 2026 KORNNAC Pharma. All rights reserved. | Privacy Policy
A liquid-filled hard capsule (LFHC) is a two-piece hard shell — made of gelatin or HPMC — that is filled with an oil, a liquid or a suspension instead of a powder, then closed and sealed so the fill cannot leak. The word "hard" is the defining one: the shell is manufactured first as two separable halves (a body and a cap), whereas a softgel shell is formed around the fill in a single rotary-die operation. That structural difference, not the fill itself, is what changes your formulation options, your shelf-life data and your cost per unit. This article defines the format precisely, walks through how a capsule is filled and sealed, and sets out the cases where a liquid fill is the wrong choice.
In the pharmacopoeial sense, a hard capsule is a two-piece shell — a longer body and a shorter cap that slides over it — traditionally filled with powder, granules or pellets. An LFHC keeps that same two-piece shell but replaces the powder with a non-solid fill: a pure oil, an oil-soluble active in a carrier, a suspension of solid particles in liquid, or a semi-solid matrix.
Two shell materials dominate. Gelatin remains the default for its film strength and long regulatory history. HPMC (hydroxypropyl methylcellulose) is the plant-based alternative, and it is the reason a liquid-filled capsule can carry a vegan or halal claim. Because the two materials behave differently with moisture and with oils, the shell choice is a formulation decision rather than a labelling afterthought — a point we return to in the brief checklist below.
A softgel is one piece, formed and sealed in the same continuous step, which makes it excellent for high-volume oil products but also locks the fill inside a plasticised shell that is comparatively thick and less tolerant of certain fill chemistries. In a hard shell the two halves are rigid and thin, so the fill is dosed into a pre-formed cavity rather than into a freshly extruded ribbon. What that buys you is freedom: the fill volume is set by the capsule size you select, the fill can be changed between batches without re-tooling a die, and the same shell can carry a liquid, a paste or a powder depending on the project. What it costs you is one additional production step — sealing — which is why LFHC lines are usually judged on their sealing capability rather than their filling speed alone.
The filling train is short, but every step has a failure mode that shows up in stability testing months later.
Typical production-line throughput, quoted fill tolerances and moisture specifications are all line-specific, so treat any published number as a starting point for the brief rather than a guaranteed outcome.
| Dimension | Liquid-filled hard capsule | Softgel | Tablet |
|---|---|---|---|
| Shell construction | Two separable halves (gelatin or HPMC), sealed after filling | One-piece plasticised shell formed around the fill | Not applicable — compressed powder mass |
| Fill types accepted | Oils, liquids, suspensions, semi-solids | Primarily oils and oil-miscible liquids | Powder, granules; liquids only after granulation |
| Shell material flexibility | Gelatin or HPMC — plant-based and halal options | Usually gelatin; HPMC-based softgels exist but are less common | Excipient-driven |
| Sealing step | Required | Not applicable | Not applicable |
| Changeover to a new fill | Shell size and pump settings | Die and ribbon set-up | Compression tooling |
| Best fit | Lipid actives, sensitive actives, multi-phase fills | High-volume single-phase oil products | High-dose, low-cost, stable powders |
The comparison that matters commercially is rarely "which is better" but "which change is cheapest at my volume". A brand already running a tablet line and moving to a lipid active is not choosing between a capsule and a tablet — it is choosing between reformulating the tablet and switching dosage form entirely.
A lipid-soluble nutrient delivered as a compressed powder has to dissolve in the gut before it can be absorbed, and that dissolution step is where much of the dose is lost. Delivering the same nutrient already dissolved in an oil carrier removes that dependency: the active arrives at the absorption site in the physical state it needs to be in.
This is also why a liquid fill can raise labelled potency without raising the input dose. Manufacturers of liquid delivery systems commonly claim substantial bioavailability gains for lipid-based nutrients — KORNNAC Pharma, for instance, publishes a figure of up to 300% for lipid-based nutrients delivered in liquid-filled hard capsules. Published bioavailability comparisons are always formulation-specific, so the number that should govern a project decision is the one generated on your own actives during pilot trials, not the headline figure on a supplier's website.
There is a second, quieter benefit: a liquid fill masks odour and taste. Volatile botanical oils and marine oils are difficult to compress into tablets without an unpleasant aftertaste, and an hermetically sealed liquid capsule contains that problem inside the shell.
A liquid fill is not automatically the better format. Three situations argue against it.
The active is stable and cheap as a powder. If the ingredient is already well absorbed, thermally stable, and sold on price per dose, a tablet or a powder-filled capsule will usually be cheaper to produce and simpler to register.
The dose is too large for the fill volume. Liquids have a practical ceiling set by capsule size and by the density of the fill. A high-dose botanical extract that fits into a single large tablet may need two or three liquid capsules to reach the same dose, which changes the product's daily-intake story on the label.
The market expects a chewable, gummy or powder format. Dosage form is a consumer-facing choice as much as a technical one. Gummies, for instance, are chosen for compliance and taste rather than for delivery precision.
If none of those applies, an LFHC is usually the stronger option — but the format decision should be recorded with the reason, because it determines which stability and fill data you will have to generate.
Vague briefs produce expensive pilot rounds. These are the parameters that change the quotation:
For the wider process — phases, timelines and how the R&D and pilot stages are sequenced — see the CDMO workflow. If your fill combines a liquid with a solid phase, the next format to understand is beadlet-in-oil; if it combines two incompatible phases that must not touch, read capsule-in-capsule explained. The liquid filled capsule range lists current commercial examples.
Is a liquid-filled hard capsule the same as a softgel? No. A softgel is a single-piece shell formed around the fill; an LFHC is a two-piece hard shell that is filled and then sealed. The distinction matters because the two formats differ in fill flexibility, shell material options and changeover cost.
Can a liquid-filled hard capsule be vegan? Yes, when the shell is HPMC rather than gelatin. HPMC is a plant-derived cellulose polymer, and it is the material that makes a vegan or halal claim possible on a liquid-filled product.
How much liquid fits in one capsule? The fill volume is set by the capsule size and by the density of the liquid. Because dense oils and light suspensions occupy different volumes for the same weight, fill volume and fill weight must be specified together rather than interchangeably.
Why does a liquid capsule need to be sealed? A two-piece shell relies on cap-to-body overlap alone to stay closed, which is adequate for powder but marginal for a liquid that can migrate into the joint. Sealing the joint closes that path and is the step that makes the format transport-safe.
Do liquid-filled capsules need different stability testing? The fill, not just the shell, drives the test design. Oils oxidise, suspensions sediment and volatile actives migrate, so accelerated stability work should be planned around the specific fill rather than around a generic capsule protocol.
A liquid-filled hard capsule (LFHC) is a two-piece hard shell — made of gelatin or HPMC — that is filled with an oil, a liquid or a suspension instead of a powder, then closed and sealed so the fill cannot leak. The word "hard" is the defining one: the shell is manufactured first as two separable halves (a body and a cap), whereas a softgel shell is formed around the fill in a single rotary-die operation. That structural difference, not the fill itself, is what changes your formulation options, your shelf-life data and your cost per unit. This article defines the format precisely, walks through how a capsule is filled and sealed, and sets out the cases where a liquid fill is the wrong choice.
In the pharmacopoeial sense, a hard capsule is a two-piece shell — a longer body and a shorter cap that slides over it — traditionally filled with powder, granules or pellets. An LFHC keeps that same two-piece shell but replaces the powder with a non-solid fill: a pure oil, an oil-soluble active in a carrier, a suspension of solid particles in liquid, or a semi-solid matrix.
Two shell materials dominate. Gelatin remains the default for its film strength and long regulatory history. HPMC (hydroxypropyl methylcellulose) is the plant-based alternative, and it is the reason a liquid-filled capsule can carry a vegan or halal claim. Because the two materials behave differently with moisture and with oils, the shell choice is a formulation decision rather than a labelling afterthought — a point we return to in the brief checklist below.
A softgel is one piece, formed and sealed in the same continuous step, which makes it excellent for high-volume oil products but also locks the fill inside a plasticised shell that is comparatively thick and less tolerant of certain fill chemistries. In a hard shell the two halves are rigid and thin, so the fill is dosed into a pre-formed cavity rather than into a freshly extruded ribbon. What that buys you is freedom: the fill volume is set by the capsule size you select, the fill can be changed between batches without re-tooling a die, and the same shell can carry a liquid, a paste or a powder depending on the project. What it costs you is one additional production step — sealing — which is why LFHC lines are usually judged on their sealing capability rather than their filling speed alone.
The filling train is short, but every step has a failure mode that shows up in stability testing months later.
Typical production-line throughput, quoted fill tolerances and moisture specifications are all line-specific, so treat any published number as a starting point for the brief rather than a guaranteed outcome.
| Dimension | Liquid-filled hard capsule | Softgel | Tablet |
|---|---|---|---|
| Shell construction | Two separable halves (gelatin or HPMC), sealed after filling | One-piece plasticised shell formed around the fill | Not applicable — compressed powder mass |
| Fill types accepted | Oils, liquids, suspensions, semi-solids | Primarily oils and oil-miscible liquids | Powder, granules; liquids only after granulation |
| Shell material flexibility | Gelatin or HPMC — plant-based and halal options | Usually gelatin; HPMC-based softgels exist but are less common | Excipient-driven |
| Sealing step | Required | Not applicable | Not applicable |
| Changeover to a new fill | Shell size and pump settings | Die and ribbon set-up | Compression tooling |
| Best fit | Lipid actives, sensitive actives, multi-phase fills | High-volume single-phase oil products | High-dose, low-cost, stable powders |
The comparison that matters commercially is rarely "which is better" but "which change is cheapest at my volume". A brand already running a tablet line and moving to a lipid active is not choosing between a capsule and a tablet — it is choosing between reformulating the tablet and switching dosage form entirely.
A lipid-soluble nutrient delivered as a compressed powder has to dissolve in the gut before it can be absorbed, and that dissolution step is where much of the dose is lost. Delivering the same nutrient already dissolved in an oil carrier removes that dependency: the active arrives at the absorption site in the physical state it needs to be in.
This is also why a liquid fill can raise labelled potency without raising the input dose. Manufacturers of liquid delivery systems commonly claim substantial bioavailability gains for lipid-based nutrients — KORNNAC Pharma, for instance, publishes a figure of up to 300% for lipid-based nutrients delivered in liquid-filled hard capsules. Published bioavailability comparisons are always formulation-specific, so the number that should govern a project decision is the one generated on your own actives during pilot trials, not the headline figure on a supplier's website.
There is a second, quieter benefit: a liquid fill masks odour and taste. Volatile botanical oils and marine oils are difficult to compress into tablets without an unpleasant aftertaste, and an hermetically sealed liquid capsule contains that problem inside the shell.
A liquid fill is not automatically the better format. Three situations argue against it.
The active is stable and cheap as a powder. If the ingredient is already well absorbed, thermally stable, and sold on price per dose, a tablet or a powder-filled capsule will usually be cheaper to produce and simpler to register.
The dose is too large for the fill volume. Liquids have a practical ceiling set by capsule size and by the density of the fill. A high-dose botanical extract that fits into a single large tablet may need two or three liquid capsules to reach the same dose, which changes the product's daily-intake story on the label.
The market expects a chewable, gummy or powder format. Dosage form is a consumer-facing choice as much as a technical one. Gummies, for instance, are chosen for compliance and taste rather than for delivery precision.
If none of those applies, an LFHC is usually the stronger option — but the format decision should be recorded with the reason, because it determines which stability and fill data you will have to generate.
Vague briefs produce expensive pilot rounds. These are the parameters that change the quotation:
For the wider process — phases, timelines and how the R&D and pilot stages are sequenced — see the CDMO workflow. If your fill combines a liquid with a solid phase, the next format to understand is beadlet-in-oil; if it combines two incompatible phases that must not touch, read capsule-in-capsule explained. The liquid filled capsule range lists current commercial examples.
Is a liquid-filled hard capsule the same as a softgel? No. A softgel is a single-piece shell formed around the fill; an LFHC is a two-piece hard shell that is filled and then sealed. The distinction matters because the two formats differ in fill flexibility, shell material options and changeover cost.
Can a liquid-filled hard capsule be vegan? Yes, when the shell is HPMC rather than gelatin. HPMC is a plant-derived cellulose polymer, and it is the material that makes a vegan or halal claim possible on a liquid-filled product.
How much liquid fits in one capsule? The fill volume is set by the capsule size and by the density of the liquid. Because dense oils and light suspensions occupy different volumes for the same weight, fill volume and fill weight must be specified together rather than interchangeably.
Why does a liquid capsule need to be sealed? A two-piece shell relies on cap-to-body overlap alone to stay closed, which is adequate for powder but marginal for a liquid that can migrate into the joint. Sealing the joint closes that path and is the step that makes the format transport-safe.
Do liquid-filled capsules need different stability testing? The fill, not just the shell, drives the test design. Oils oxidise, suspensions sediment and volatile actives migrate, so accelerated stability work should be planned around the specific fill rather than around a generic capsule protocol.
© 2026 KORNNAC Pharma. All rights reserved. | Privacy Policy